INTRODUCTION {#s1}
============

Cancer is a complex group of diseases with many possible causes. It can be partly explain as a result of a progressive accumulation of mutations in cellular DNA, which provides a selective growth advantage to cancer cells and facilitates metastasis. Hotspot mutations are frequently present within oncogenes while some other aberrations are found in tumor suppressor genes in common solid tumors. The deregulation of certain signaling pathways, together with chromosomal abnormalities, has been identified in different solid tumors. Different oncogenic events have been described in cancer including mainly mutations in the RAS/RAF/MAPK and the PIK3/PTEN/AKT pathways. Therefore, mutations affecting the coding sequences of these specific genes are the hallmark of the disease and are currently targeted in clinical trials \[[@R1]\].

Our knowledge of cancer genomics has been enabled by the genome sequencing and other high-throughput omics technologies, leading to the discovery of new targets \[[@R2]\]. The development of targeted drugs has allowed for a more precise and personalized therapy, something which could be of major benefit to the patients. This drug sensitivity approach is reinforced by the efficacy shown in clinical trials using epidermal growth factor receptor (EGFR) and BRAF tyrosine kinase inhibitors (TKIs) \[[@R3]--[@R6]\]. The discovery of activating mutations located in the tyrosine kinase domains of EGFR has expanded the therapeutic options of lung cancer patients since they can be treated by EGFR-TKIs \[[@R7]\]. In metastatic colorectal cancer (mCRC) patients whose tumors are wild type for all KRAS/NRAS alleles, the administration of monoclonal antibodies against EGFR, such as cetuximab and panitumumab, in combination with conventional chemotherapy, substantially improves survival \[[@R8]--[@R10]\]. The presence of *KRAS* and *NRAS* mutations acts as a negative predictor to sensitivity to anti-EGFR monoclonal antibody therapy and, therefore, has caused an important change in the treatment of mCRC. The presence of the *BRAF* V600E activating mutation, found in approximately half of the diagnosed melanomas, is a turning point in the treatment of the metastatic disease through BRAF-TIKs \[[@R3], [@R11]\]. The use of targeted drugs against the oncogenic alterations of the *KRAS* gene and/or its downstream components (e.g. BRAF, MEK) seems to be a promising approach to cancer therapeutics either alone or in combination with other targeted agents \[[@R12]--[@R14]\].

Somatic mutation analysis has become a useful tool in selecting personalized therapies for many solid tumors. Mutation profiling can assist in the prognosis, prediction and treatment of solid tumors. Thus, molecular stratification for genotype-directed therapy could be required \[[@R15]\]. The mass spectrometry technique, matrix-assisted laser desorption/ionization-time of flight, has been used to assess point mutations across different solid tumors \[[@R16]\]. The Sequenom MassARRAY technology, in combination with a commercial kit called OncoCarta v1.0, was used to screen 238 somatic mutations across 19 oncogenes. This mutation panel interrogates somatic changes in oncogenes with known responses or resistance-targeted therapy. Custom assays can be also incorporated into the whole design, permitting the detection of specific target genes.

The goal of this study was to characterize the presence of common somatic mutations affecting known oncogenes in resected solid tumors that could provide potential therapeutic targets.

RESULTS {#s2}
=======

Patient characteristics {#s2_1}
-----------------------

The median age of the patients was 58 years. The study included individuals with advanced-stage tumors who had received at least one line of treatment (67.4%).

The different tumor types representing the 197 enrolled patients were colorectal cancer (n= 75), breast cancer (n=73), ovarian cancer (n=10), lung cancer (n=9, 8 adenocarcinoma and 1 squamous), endometrial cancer (n=8) and other tumor types (n=20), including cervical, gastric, pancreatic, melanoma, anal, appendiceal, esophageal, renal, oral cavity and thyroid tumors. Formalin-fixed paraffin-embedded (FFPE) primary tumor samples were obtained for 123 (62.4%) subjects with nodal and/or metastatic tumor samples being available for a further 73 (37.1%) patients. The clinical characteristics of the patients have been included in Table [1](#T1){ref-type="table"}. Colorectal and breast carcinoma were the two most represented tumor types with 75 and 73 cases enrolled, respectively ([Supplementary Table S1](#SD1){ref-type="supplementary-material"}).

###### Classification of the samples studied by age and clinical characteristics (N=197)

  Clinical characteristic                      N (%)
  -------------------------------------------- ------------
  **Age (years)**                              
   Median (Range)                              58 (27-88)
  **Gender**                                   
   Female                                      129 (65.5)
   Male                                        68 (34.5)
  **Tumor type**                               
   Colorectal cancer                           75 (38.1)
   Breast cancer                               73 (37.1)
   Ovarian cancer                              10 (5.1)
   Lung cancer                                 9 (4.6)
   Endometrial cancer                          8 (4.0)
   Others[\*](#tfn_001){ref-type="table-fn"}   20 (10.1)
   Unknown                                     2 (1.0)
  **Prior therapy**                            
   No treatment                                52 (26.4)
   One line of treatment                       70 (35.5)
   Two lines of treatment                      32 (16.2)
   Three or more lines of treatment            31 (15.7)
   Unknown                                     12 (6.0)
  **Origen of the samples**                    
   Primary tumor                               123 (62.4)
   Metastasis                                  73 (37.1)
   Unknown                                     1 (0.5)

Others include cervical (4), gastric (4), pancreas (4), melanoma (2), anal (1), appendiceal (1), esophageal (1), renal (1), oral cavity (1) and thyroid (1) cancer

Mutational detection {#s2_2}
--------------------

A total of 197 samples were subjected to a hotspot mutation screening of 25 known cancer genes using the OncoCarta Panel v1.0 (Sequenom, San Diego, CA) and two customized panels. Mutations with frequencies higher than 10% were detected with high accuracy. One hundred and thirty-four oncogenic mutations were detected in 97 (49.2%) patients, and these mutations were found in the *KRAS*, *PIK3CA*, *KIT*, *MET*, *RET*, *NRAS*, *EGFR*, *BRAF*, *CDK4*, *GNAS*, *ABL1*, *AKT1*, *AKT3*, *PDGFRA*, *IDH1*, *ERBB2* and *ERBB3* genes (Figure [1](#F1){ref-type="fig"} and [Supplementary Figure S1](#SD1){ref-type="supplementary-material"}). A total of 49 different oncogenic mutations were identified, 33 (80.5%) of them base transitions. The RAS/RAF/MAPK and the PIK3/AKT pathways were the most frequently mutated with 50 (51.5%) and 35 (36.1%) tumors mutated, respectively. Mutations in the *KRAS* gene were detected in 40/97 (41.2%) patients whereas mutations in the *PIK3CA* gene were detected in 30/97 (30.9%) patients. See [Supplementary Table S2](#SD1){ref-type="supplementary-material"}. Furthermore, 31 patients had mutations in at least two genes (32.0%), 2 of them carriers of synchronous mutations within the *PIK3CA* oncogene. Moreover, 3 of the samples carried more than two different mutations.

![Genomic mutations found across the different solid tumor types enrolled in the study\
Selected genes are mutated in at least one tumor sample. Samples with mutations are shown in black. **A.** Colorectal samples; **B.** Breast cancer samples; **C.** Ovarian cancer samples; **D.** Lung cancer samples; **E.** Endometrial cancer samples, **F.** Other tumor samples (oral cavity, cervical, melanoma, gastric, anal, renal, pancreatic, appendiceal, esophageal and thyroid cancers). The histogram represents the percentage of gene mutation across the different tumor types. Colorectal cancer and breast cancer are represented with dots and with lines, respectively, while all other tumors are represented together in black.](oncotarget-07-22543-g001){#F1}

Twenty of the 31 cases with co-occurrence mutations (64.5%) were initially diagnosed with colorectal cancer. First, the co-occurrence of mutations within *KRAS* and *PIK3CA* was found in 8 (25.8%) patients. *KRAS* mutations were mainly located within exon 2, affecting G12 and G13 amino-acids, whereas *PIK3CA* mutations were mainly located in the helical domain, in positions 420, 452 and 546. Second, the mutations found in *KIT* and *PIK3CA* were found in 6 (19.4%) patients. These mutations affected amino-acids D52 and E839 in *KIT* and E542, E545 and H1047 in *PIK3CA*. Interestingly, mutation E839K in *KIT* appeared exclusively with the *PIK3CA* E452K mutation. Last, the co-mutations in *KIT* and *RET* were present in 4 (12.9%) patients. These mutations were D52N in the *KIT* gene and C634W in the *RET* gene (Table [2](#T2){ref-type="table"} and Figure [2](#F2){ref-type="fig"}).

![Genomic co-occurrence mutations found across those tumor samples with two or more mutations\
The length of the arc corresponds to the frequency of mutations in the first gene, and the width of the ribbon corresponds to the percentage of patients who also had a mutation in the second gene. This diagram was obtained using the Circos software (<http://mkweb.bcgsc.ca/tableviewer/visualize/>).](oncotarget-07-22543-g002){#F2}

###### Samples with co-occurrence of mutations

  Sample   Type of Cancer         Most frequently mutated genes   Least frequently mutated genes                                                                  
  -------- ---------------------- ------------------------------- -------------------------------- ----------- ----------- ---------- ---------------- ---------- ---------------
  INV063   Breast, liver mets     G12D                                                                                     *ABL1*     Y253H                       
  INV110   Rectal                 G13D                                                                                     *AKT1*     E17K                        
  INV086   Colon                  G13D                                                                                     *AKT3*     G171R                       
  INV034   Cervix                 G12D                                                                                     *GNAS*     R201H                       
  INV198   Colon                  G12D                                                                                     *GNAS*     R201H                       
  INV161   Colon                  G12C                                                                                     *KIT*      D52N                        
  INV005   Rectal, lung mets      G12D                                                                                     *MET*      R970C                       
  INV017   Rectal                 A146V                                                                                    *NRAS*     G12S                        
  INV186   Colon                  G13D                                                                                     *NRAS*     G13D                        
  INV016   Colon                  **G12D**                        **E542K**                        **D52N**    **C634W**                                          
  INV163   Colon                  **G13D**                        **E542K & H1047R**               **D52N**                                                       
  INV042   Breast                 **Q61R**                        **C420R**                                                *CDK4*     R24C             *EGFR*     P772_H773InsV
  INV028   Colon                  **G12D**                        **E542K**                                                                                       
  INV059   Colon                  **G12S**                        **E542K**                                                                                       
  INV084   Colon                  **G13D**                        **Q546R**                                                                                       
  INV181   Colon                  **G12V**                        **Y1021C**                                                                                      
  INV185   Colon                  **G12C**                        **G1049R**                                                                                      
  INV001   Colon                  G12D                                                                         C634Y                                              
  INV045   Colon                                                  C420R                                                    *BRAF*     V600E                       
  INV054   Colon                                                  G1049R                                                   *EGFR*     D770_N771\>AGG              
  INV177   Breast                                                 **E545K**                        **D52N**                                                       
  INV036   Cervix                                                 **E542K**                        **E839K**                                                      
  INV141   Colon, liver mets                                      **H1047R**                       **D52N**    **C634W**                                          
  INV126   Breast                                                 **E542K**                        **E839K**                                                      
  INV088   Breast, pleural mets                                   **E545K & G1049R**                                                                              
  INV134   Breast, lung mets                                                                       L576P                   *MET*      N375S                       
  INV055   Rectal                                                                                  D52N                    *PDGFRA*   D842V                       
  INV081   Colon                                                                                   **D52N**    **C634W**                                          
  INV071   Breast, pleural mets                                                                    **D52N**    **C634W**                                          
  INV011   Kidney                                                                                                          *MET*      R970C            *BRAF*     L597S
  INV023   Ovary                                                                                                           *NRAS*     G13D             *PDGFRA*   D1071N

Most and least frequently mutated genes in samples with co-occurrence mutations

mets: metastasis

Bold represent the most frequent associations: *KRAS* + *PIK3CA*; *PIK3CA* + *KIT* and *KIT* + *RET*

The concordance between the OncoCarta Panel v1.0 and the customized panels was 90.0%. Moreover, the concordance between the OncoCarta Panel v1.0 and Junior NGS technology was 88.0% (data not shown). In the present study, taking into account the mutations with frequencies higher than 10%, the sensibility and specificity were 79.0% and 93.5%, respectively. Those samples with non-concordant results had low allelic frequency mutations.

Association with clinical characteristics {#s2_3}
-----------------------------------------

Association with clinical characteristics was performed for the two most represented tumor types.

### Colorectal cancer {#s2_3_1}

Overall, mutations were detected in 48 of 75 (64.2%) available FFPE tumors, predominantly in primary tumor samples (37/48, 77.1%) (Table [3](#T3){ref-type="table"} and [Supplementary Table S1](#SD1){ref-type="supplementary-material"}). Specifically, *KRAS*, *PIK3CA* and *KIT* mutations were detected in 31/48 (64.6%), 11/48 (22.9%), 8/48 (16.7%) tumor specimens, respectively. There was (66/75) 88.0% concordance for FFPE tumoral mutation status between the OncoCarta Sequenom panel and the next generation sequencing (NGS) Junior (Roche). Mutations in five of the samples found by NGS were not detected by Sequenom (*KRA*S p.G12C 10.8%, p.Q61K 47.1% and p.A146T 11.6%, and p.Q61L 13.7% and *BRAF* p.V600E 12.3%; percentages represent the frequency of mutant alleles). Four of them were close to the 10% threshold established. Among the other 4 samples, mutations were detected only by the Sequenom technology (*KRAS* p.G12D 15.0% and p.G13D 15.2%, *NRAS* p.G13D 21.4% and *PIK3CA* p.H1047R 23.0%).

###### Mutation distribution across colorectal cancer samples

  Sample   Location      Type         Gene       Mutation   %M       Gene       Mutation         %M     Gene       Mutation   %M     Gene       Mutation   %M
  -------- ------------- ------------ ---------- ---------- -------- ---------- ---------------- ------ ---------- ---------- ------ ---------- ---------- ------
  INV001   Left colon    Primary      *KRAS*     G12D       42.7     *RET*      C634Y            10.5                                                      
  INV004   Left colon    Primary      *KRAS*     A146V      23.3                                                                                           
  INV014   Left colon    Primary      *KRAS*     G12D       35.3                                                                                           
  INV086   Left colon    Primary      *KRAS*     G13D       39.8     *AKT3*     G171R            15.1                                                      
  INV104   Left colon    Primary      *KRAS*     G12V       31.6                                                                                           
  INV164   Left colon    Primary      *KRAS*     G12D       33.7                                                                                           
  INV060   Left colon    Metastasis   *KRAS*     Q61R       36.9                                                                                           
  INV008   Left colon    Primary      *PIK3CA*   G1049R     14.5                                                                                           
  INV054   Left colon    Primary      *PIK3CA*   G1049R     10.6     *EGFR*     D770_N771\>AGG   11.1                                                      
  INV138   Left colon    Metastasis   *PIK3CA*   G1049R     10.7                                                                                           
  INV081   Left colon    Primary      *KIT*      D52N       27.6     *RET*      C634W            31.8                                                      
  INV161   Left colon    Primary      *KIT*      D52N       14.6     *KRAS*     G12C             24.1                                                      
  INV141   Left colon    Metastasis   *KIT*      D52N       47.2     *PIK3CA*   H1047R           23.0   *RET*      C634W      42.4                         
  INV154   Left colon    Metastasis   *MET*      N375S      34.2                                                                                           
  INV180   Left colon    Primary      *AKT1*     E17K       36.6                                                                                           
  INV186   Left colon    Primary      *KRAS*     G13D       15.2     *NRAS*     G13D             21.4                                                      
  INV196   Left colon    Primary      *KRAS*     G12V       14.3                                                                                           
  INV201   Left colon    Primary      *NRAS*     G12D       24.1                                                                                           
  INV016   Right colon   Primary      *KRAS*     G12D       10.0     *KIT*      D52N             10.4   *PIK3CA*   E542K      13.4   *RET*      C634W      23.5
  INV026   Right colon   Primary      *KRAS*     G12D       35.0                                                                                           
  INV028   Right colon   Primary      *KRAS*     G12D       14.0     *PIK3CA*   E542K            14.4                                                      
  INV031   Right colon   Primary      *KRAS*     G12D       38.6                                                                                           
  INV059   Right colon   Primary      *KRAS*     G12S       23.4     *PIK3CA*   E542K            19.4                                                      
  INV066   Right colon   Primary      *KRAS*     G13D       40.9                                                                                           
  INV084   Right colon   Primary      *KRAS*     G13D       24.6     *PIK3CA*   Q546R            12.7                                                      
  INV163   Right colon   Primary      *KRAS*     G13D       27.0     *KIT*      D52N             20.0   *PIK3CA*   E542K      14.6   *PIK3CA*   H1047R     23.1
  INV082   Right colon   Metastasis   *KRAS*     A59T       19.5                                                                                           
  INV045   Right colon   Primary      *BRAF*     V600E      15.7     *PIK3CA*   C420R            23.3                                                      
  INV181   Right colon   Primary      *KRAS*     G12V       31.1     *PIK3CA*   Y1021C           72.0                                                      
  INV185   Right colon   Primary      *KRAS*     G12C       15.0     *PIK3CA*   G1049R           15.0                                                      
  INV193   Right colon   Primary      *KRAS*     G12S       26.9                                                                                           
  INV197   Right colon   Primary      *BRAF*     V600E      11.5                                                                                           
  INV198   Right colon   Primary      *KRAS*     G12D       67.5     *GNAS*     R201H            31.1   *IDH1*     R132C      44                           
  INV017   Rectum        Primary      *KRAS*     A146V      10.8     *NRAS*     G12S             46.0                                                      
  INV110   Rectum        Primary      *KRAS*     G13D       36.5     *AKT1*     E17K             33.9                                                      
  INV005   Rectum        Metastasis   *KRAS*     G12D       49.4     *MET*      R970C            48.9                                                      
  INV018   Rectum        Primary      *NRAS*     Q61R       23.8                                                                                           
  INV020   Rectum        Primary      *KIT*      D52N       19.8                                                                                           
  INV055   Rectum        Primary      *KIT*      D52N       27.8     *PDGFRA*   D842V            20.5                                                      
  INV030   Rectum        Metastasis   *KIT*      D52N       *16.4*                                                                                         
  INV147   Rectum        Primary      *EGFR*     G719S      *22.7*                                                                                         
  INV079   Unknown       Primary      *KRAS*     G12D       *58.3*                                                                                         
  INV145   Unknown       Primary      *KRAS*     A146T      *16.7*                                                                                         
  INV184   Unknown       Primary      *MET*      N375S      *27.5*                                                                                         
  INV190   Unknown       Metastasis   *KRAS*     G12C       *33.4*                                                                                         
  INV191   Unknown       \-           *KRAS*     G12V       *15.4*                                                                                         

%M represent the percentage of mutant alleles in each reported gene

### Breast cancer {#s2_3_2}

Overall, mutations were detected in 34 of 73 (46.6%) available FFPE tumors, predominantly in the metastatic tissue (23/34, 67.6%) (See Table [4](#T4){ref-type="table"} and [Supplementary Table S1](#SD1){ref-type="supplementary-material"}). Specifically, *PIK3CA* and *KIT* mutations were detected in 16 (47.0%), and 8 (23.5%), respectively, of the tumor specimens. There was (70/73) 96.0% concordance for FFPE tumoral mutation status between the OncoCarta Sequenom panel and the NGS Junior. Two samples showed *PIK3CA* mutations in NGS but not in Sequenom (p.E542K, 29% and p.H1047L 11%; percentages represent the frequency of mutant alleles). The last reported mutation is close to the threshold of detection by Sequenom technology. Finally, the last, fourth, sample showed *AKT1* mutation in NGS, but not in Sequenom (p.E17K 44.8%; percentage represents the frequency of mutant alleles).

###### Mutation distribution across breast cancer samples

  Sample   Molecular subtype   Histology        Type         Gene       Mut             %M       Gene       Mut      %M     Gene     Mut             %M       Gene     Mut    %M
  -------- ------------------- ---------------- ------------ ---------- --------------- -------- ---------- -------- ------ -------- --------------- -------- -------- ------ ------
  INV174   Luminal A           Ductal           Primary      *KIT*      D52N            *15.3*                                                                                
  INV096   Luminal A           Ductal           Metastasis   *KIT*      D52N            *23.8*                                                                                
  INV095   Luminal A           Ductal           Metastasis   *KIT*      K550_K558del    *17.6*                                                                                
  INV107   Luminal A           Lobular          Metastasis   *PIK3CA*   N345K           *12.5*                                                                                
  INV033   Luminal A           Ductal           Metastasis   *PIK3CA*   E542K           *32.0*                                                                                
  INV117   Luminal A           Ductal           Metastasis   *PIK3CA*   M1043I          *15.5*                                                                                
  INV072   Luminal A           Lobular          Metastasis   *PIK3CA*   H1047R          *15.8*                                                                                
  INV205   Luminal A           Ductal           Metastasis   *PIK3CA*   H1047R          *37.7*                                                                                
  INV169   Luminal B           Ductal           Primary      *AKT1*     E17K            *20.4*                                                                                
  INV170   Luminal B           Ductal           Metastasis   *AKT1*     E17K            *59.9*                                                                                
  INV128   Luminal B           Ductal           Metastasis   *EGFR*     H773_V774insH   *30.9*                                                                                
  INV071   Luminal B           Lobular          Metastasis   *KIT*      D52N            *14.3*   *RET*      C634W    48.3                                                     
  INV073   Luminal B           Ductal           Metastasis   *KIT*      Y553_Q556del    *11.3*                                                                                
  INV155   Luminal B           Not specified    Primary      *MET*      N375S           *35.1*                                                                                
  INV173   Luminal B           Ductal           Metastasis   *PIK3CA*   E542K           *37.8*                                                                                
  INV126   Luminal B           Lobular          Primary      *PIK3CA*   E542K           *12.0*   *KIT*      E839K    14.4                                                     
  INV105   Luminal B           Ductal           Metastasis   *PIK3CA*   E545K           *57.4*                                                                                
  INV177   Luminal B           Ductal           Primary      *PIK3CA*   E545K           *59.3*   *KIT*      D52N     10.0                                                     
  INV077   Luminal B           Ductal           Metastasis   *PIK3CA*   E545K           *30.4*                                                                                
  INV088   Luminal B           Ductal           Metastasis   *PIK3CA*   E545K           *66.3*   *PIK3CA*   G1049R   19.2                                                     
  INV101   Luminal B           Ductal           Primary      *PIK3CA*   H1047R          *20.5*                                                                                
  INV092   Luminal B           Ductal           Primary      *RET*      C634W           *31.3*                                                                                
  INV042   Basal like          Ductal           Primary      *PIK3CA*   C420R           *12.1*   CDK4       R24C     13.2   *EGFR*   P772_H773insV   *13.2*   *KRAS*   Q61R   12.4
  INV057   Basal like          Ductal           Primary      *PIK3CA*   H1047R          *18.9*                                                                                
  INV044   Basal like          Lobular          Metastasis   *PIK3CA*   H1047R          *19.5*                                                                                
  INV069   Her2                Ductal           Metastasis   *PIK3CA*   M1043I          *49.6*                                                                                
  INV074   Her2                Tubule-lobular   Metastasis   *PDGFRA*   D842V           *32.2*                                                                                
  INV094   Her2                Ductal           Primary      *KRAS*     G12D            *14.8*                                                                                
  INV134   Her2                Ductal           Metastasis   *KIT*      L576P           *13.3*   *MET*      N375S    17.6                                                     
  INV070   Her2                Ductal           Metastasis   *CDK4*     R24H            *10.4*                                                                                
  INV063   Her2                Ductal           Metastasis   *ABL1*     Y253H           *12.2*   *KRAS*     G12D     22.6                                                     

Mut, mutation; %M represent the percentage of mutant alleles in each reported gene

Personalized therapy {#s2_4}
--------------------

A total of 101 patients could benefit from targeted therapies. Seventy-five of the patients presented potential actionable mutations, whereas an additional 26 patients with colorectal cancer had *KRAS* wild type status. Among these 101 patients, 28 received genotype-directed therapy (28.0%), including 20 colorectal cancer patients that received clinically available agents. Five of these 20 colorectal cancer patients (25.0%) received anti-EGFR therapy, whereas the rest (15 patients) received other available therapies.

The remaining 8 patients were enrolled in clinical trials. These patients had breast or gynecological malignancies. Seven of them carried a mutation in the *PI3KCA* gene, and one had a mutation in the *ERBB2* gene. Among the *PI3KCA* mutation carriers, 5 received PI3K/AKT inhibitors. The other 3 received other target drugs, including an anti-IGF1 therapy in one case and an anti-ERBB3 therapy in two patients (See [Supplementary Figure S2](#SD1){ref-type="supplementary-material"}).

A total of 73 patients who could possibly have benefitted from targeted therapies were not treated. The most common reasons for not offering targeted therapies according to the mutations found were diverse. Consequently, twenty-five patients (34.3%) followed standard therapies. Another 19 (26%) patients did not progress during the study period and did not require a new treatment. The rest 29 (39.7%) were not eligible due to co-morbidities, poor performance status, concurrent secondary neoplasm or loss of follow up.

DISCUSSION {#s3}
==========

Many different solid tumors contain hotspot mutations within oncogenes that confer a relevant susceptibility or resistance to targeted anticancer therapies. A comprehensive characterization of several cancer genomes has been made possible as a result of the development of NGS technologies. At present, however, these techniques are still not fully cost-effective for the medium-sized clinical laboratory. The analysis of key cancer-driving mutations using mass-spectrometry is a cost-effective, sensitive high throughput approach for identifying mutations of clinical relevance to molecular-based therapy \[[@R17]\].

Sequenom technology has been recently approved for clinical diagnosis, allowing mutation frequencies of as low as 1% to be detected. Although in the present study, mutations with frequencies higher than 10% were considered to be positive, samples were deeply evaluated for their tumor content, and only sections containing more than 30% tumor cells were considered in order to detect targetable aberrations. This threshold percentage was established by others as an accurate and detectable level of rare alleles \[[@R17]--[@R19]\]. The present approach focused only on oncogenes hotspots and did not contemplate other mutations or tumor suppressors. Furthermore, the infrequent variations might not have any association with therapy. Therefore, this methodology makes it possible for a medium-sized laboratory to analyse multiple key hotspot mutations rapidly (within 3 days) and without complex bioinformatics analysis tools at a moderate price. At present, NGS technology is becoming more accessible, and the analysis is being simplified. Sequenom technology, however, remains a good validation technology and is optimal when only hotspots are pursued.

In the present study, we have characterized the mutation status of 25 known cancer genes in a large series of 197 solid tumors from various anatomical sites using the Sequenom Platform. The mutation sites included in the Sequenom OncoCarta Panel v1.0 assay are frequently seen in many different types of solid tumors and are clinically actionable. Mutations in 17 different genes at 49 different nucleotide positions were detected in 97 of our cancer patients, of which 28 received targeted therapies. Thus, the overall rate of success in matching patients to personalized treatments was 28 out of 97 (28.0%), similar to other recently published studies \[[@R20]--[@R22]\]. This rate includes 20 CRC samples treated both by anti-EGFR, as well as other available therapies. The remaining 8 patients treated were enrolled in clinical trials, most of them against PI3K/AKT inhibitors, in accordance with other publications \[[@R23]\]. In the present series, the *KRAS* and the *PIK3CA* genes were the most frequently mutated genes in 41.2% and 30.9% of the mutated patients, respectively. Mutations in these genes disrupt many different and overlapping signaling pathways, including the PI3K/AKT and ERK/MAPK, influencing important cellular processes. Cross-validation of detected mutations was feasible by two customized mass-spectrometry panels and NGS Junior 454 Roche technology with a concordance rate of 90.0% and 88.0%, respectively. Concordance was considered when the same alleles at similar mutation frequencies were detected by the two different panels or techniques. MassARRAY technology\'s high sensibility and specificity made the results obtained with this platform highly reproducible.

Colorectal and breast cancer were the two most represented tumor types with 75 and 73 cases enrolled, respectively. Among colorectal cancer samples, mutations were detected in 64.0% of the analyzed tumors, a similar ratio to those previously published \[[@R17], [@R24]--[@R26]\]. In the colorectal cancer set, *KRAS* (42.5%), *PIK3CA* (17.8%) and *KIT* (10.9%) were the most frequently mutated genes. Frequencies for both *KRAS* and *PIK3CA* were similar to the COSMIC database and to those of other publications (<http://cancer.sanger.ac.uk/cosmic> and <http://www.cbioportal.org/>) (See [Supplementary Table S3](#SD1){ref-type="supplementary-material"}) \[[@R17], [@R24], [@R27]\]. Furthermore, sporadic mutations appeared across *RET*, *BRAF*, *EGFR*, *AKT1*, *AKT3*, *MET*, *NRAS*, *PDGFRA*, *IDH1* and *ERBB3* \[[@R24]\].

Among breast cancer samples, mutations were detected in 46.6% of the analyzed tumors, specifically in *PIK3CA* and *KIT*. Mutations among other genes were present in less than 5%, a rate similar to those of the COSMIC database and other studies such as The Cancer Genome Atlas Network (See [Supplementary Table S3](#SD1){ref-type="supplementary-material"}) \[[@R21], [@R28]--[@R30]\]. *PIK3CA* mutations were found in 7 (46.7%) luminal B, 4 (26.7%) luminal A, 3 (20.0%) basal-like and 1 (6.7%) HER2 subtypes (Breast cancer subtypes according to Perou and colleagues, 2000) \[[@R31]\]. Nevertheless, half of all the HER2 subtype tumors carried at least one mutation, and *PIK3CA* mutations were more frequently found in estrogen receptor-positive cancers compared to triple negative breast cancer \[[@R28]\].

At present, KIT mutations are without clinical implications in the current therapeutical approach to colorectal and breast cancer.

The present work focused on individuals with advanced solid tumors and potential candidates to phases I/II clinical trials due to initial treatment failure. Variations in frequencies between our data and other reports may be attributed to advanced tumor selection and the number of samples analyzed.

Interestingly, one third of the patients with mutated tumors had two genes altered, of which two thirds were initially diagnosed as colorectal cancer. Two patients carried synchronous mutations within the *PIK3CA* oncogene. Among breast cancer samples, co-occurrence appeared mainly in *PIK3CA* and *KIT*. In the colorectal cancer cases, however, co-mutation was observed most frequently in the *KRAS* and *PIK3CA* genes. The *KRAS*, *NRAS* and *BRAF* mutations in colorectal cancer are normally mutually exclusive. Conversely, the coexistence of mutations in *KRAS* and *PIK3CA* has been described in a significant percentage of colorectal tumors, confirming the parallel activation of ERK/MAPK and PI3K/AKT signaling convergent pathways \[[@R15], [@R32]\].

Remarkably, the co-occurrence of mutations within *KRAS* and *PIK3CA* was the most common, in 8 (25.8%) patients. *KRAS* mutations were mainly located within exon 2, affecting the functionally G12 and G13 amino-acids. Co-existent *PIK3CA* mutations were mainly located in the helical domain, in positions 420, 452 and 546. The coexistence of *PIK3CA* and *KRAS* mutations has been shown in several different tumors types including lung, colorectal, pancreatic and ovarian cancer \[[@R33]--[@R35]\].

Mutations found in *KIT* and *PIK3CA* were found in 6 (19.4%) patients, having an effect on amino-acids D52 and E839 in *KIT* and E542, E545 and H1047 in *PIK3CA*. Interestingly, mutation E839K in *KIT* appeared exclusively with the *PIK3CA* E452K mutation. Finally, co-mutations in *KIT* and *RET* were present in 4 (12.9%) patients. These mutations were D52N in the *KIT* gene and C634W in the *RET* gene. The co-occurrence of mutations in *KIT* and *PIK3CA* or *RET* has been described very little. Results obtained from The Cancer Genome Atlas Network for both colorectal and breast cancer showed the co-existence of mutations in these genes, although in low proportions (4.93% for *PIK3CA* and *KIT* and 1.23% for *KIT* and *RET*).

These facts suggest that cancer development may progress due to accumulation of different somatic driver mutations, affecting different pathways. At the same time, the presence of several mutations across different genes may point out tumor heterogeneity and suggest the presence of subclones. It is the detection of different clones, some of which may show resistance to therapies, a major concern, that is changing standard therapeutic approaches.

The present study aimed at identifying key alterations that may represent important targets for novel therapies. We used mass-spectrometry, an effective and high throughput approach, which successfully detected frequent cancer mutations in degraded DNA isolated from FFPE samples and provided some advantages in terms of minimizing cost and time. This technology, in combination with the OncoCarta Panel v1.0, covers up to 95% of known druggable markers for an efficient mutation screening in clinical research trials and has an elevated grade of concordance with NGS technologies.

MATERIALS AND METHODS {#s4}
=====================

Patient selection and data collection {#s4_1}
-------------------------------------

The design of the study was exploratory and prospective. A total of 213 consecutive and non-related cancer cases were recruited from September 2013 to December 2014 at the Hematology and Medical Oncology Unit of the Clinic University Hospital in Valencia, Spain. Patient eligibility criteria included clinical and histological diagnoses of advanced solid cancer or potential candidates to phases I/II clinical trials due to initial treatment failure and at least one biopsiable lesion.

Clinical information, including age, sex, tumor type, location and treatments were collected (See Table [1](#T1){ref-type="table"}). All study subjects gave written, informed consent, and the study was approved by the Biomedical Research Institute INCLIVA Ethics Committee.

Formalin-fixed paraffin-embedded (FFPE) tissues were evaluated for their tumor content, and sections containing more than 30% tumor cells were defined and cut by an expert pathologist. Genomic DNA was isolated from 4 unstained sections of 20 μm and diluted to a final solution of 10ng/μl. This was done using two extraction kits: Recover All Total Nucleic Acid Isolation kit (Ambiom, Life Technologies) and the QIAamp DNA FFPE tissue kit (QIAGEN). DNA concentration was quantified in samples by NanoDrop (NanoDrop Technologies, Wilmington, DE, USA).

Sixteen cases did not yield DNA of sufficient quantity, and were excluded from further analyses, leaving 197 samples in the study.

Sequenom MassARRAY somatic mutation genotyping {#s4_2}
----------------------------------------------

The Sequenom MassARRAY and OncoCarta Panel v1.0 were used following the manufacturer\'s protocol (Sequenom, San Diego, CA, USA; (<http://agenabio.com/oncocarta-panel>)). The panel consisted of 24 multiplex assays capable of detecting 238 mutations in 19 oncogenes. This procedure was a rapid, cost-effective method of identifying key cancer driving mutations across a large number of samples because it avoided complex bioinformatic analyses and assays were performed within two days. The amount of DNA added to the polymerase chain reaction was 20 ng per reaction. DNA was amplified using the OncoCarta PCR primer pools. Unincorporated nucleotides were inactivated by shrimp alkaline phosphatase (SAP), and a single base extension reaction was performed using extension primers that hybridize immediately adjacent to the mutations and a custom mixture of nucleotides. Salts were removed by the addition of a cation exchange resin. Multiplexed reactions were spotted onto SpectroCHIP II arrays, and DNA fragments were resolved by MALDI-TOF on the Compact Mass Spectrometer (Sequenom, San Diego, CA). Two additional customized mutation panels were used. These panels were designed in collaboration with the Cancer Genomics Group at the Vall d\'Hebron Institute of Oncology and included, in 12 multiplexes, a total of 107 somatic mutations in 15 genes. These two panels included 49 additional positions in 6 additional genes. Therefore, a total of 287 different positions in 25 oncogenes were checked (See [Supplementary Table S4](#SD1){ref-type="supplementary-material"}).

Next generation sequencing (NGS) {#s4_3}
--------------------------------

The Junior 454 Roche sequencing technology was used by the Genotyping and Genetic Diagnosis Unit (UCIM) following the manufacturer\'s protocol. This sequencing technology was used to analyze hotspot mutations in the *AKT1*, *BRAF*, *EGFR*, *KRAS*, *NRAS* and *PIK3CA* genes. A complete list of all the informed mutations is provided in [Supplementary Table S5](#SD1){ref-type="supplementary-material"}.

Statistical analyses {#s4_4}
--------------------

Data were analyzed using the Sequenom MassARRAY Typer Analyser 4.0 Software to visualize the mass spectra for mutations and to determine the frequency of mutant and wild-type alleles. The lower threshold for mutation detection has been between 5-10% \[[@R17]--[@R19]\]. In order to reduce putative false positives we set the threshold at 10%. More specifically, only mutations with frequencies higher than 10% were taken as positive results. Mutations were manually reviewed by use of visual and raw spectrum patterns. Two different personnel in the laboratory scored mutations, and no discrepancies were observed. Analyses were performed using IBM SPSS Statistics for Windows, Version 19.0. Armonk, NY: IBM Corp (IBM Corp. Released 2010).

SUPPLEMENTARY FIGURES AND TABLES {#s5}
================================
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